334 related articles for article (PubMed ID: 32943160)
1. Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants.
Camm AJ; Cools F; Virdone S; Bassand JP; Fitzmaurice DA; Arthur Fox KA; Goldhaber SZ; Goto S; Haas S; Mantovani LG; Kayani G; Grierson Turpie AG; Antoon Verheugt FW; Kakkar AK;
J Am Coll Cardiol; 2020 Sep; 76(12):1425-1436. PubMed ID: 32943160
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation: A Report From the GARFIELD-AF Registry.
Corbalan R; Bassand JP; Illingworth L; Ambrosio G; Camm AJ; Fitzmaurice DA; Fox KAA; Goldhaber SZ; Goto S; Haas S; Kayani G; Mantovani LG; Misselwitz F; Pieper KS; Turpie AGG; Verheugt FWA; Kakkar AK;
JAMA Cardiol; 2019 Jun; 4(6):526-548. PubMed ID: 31066873
[TBL] [Abstract][Full Text] [Related]
3. Label Adherence of Direct Oral Anticoagulants Dosing and Clinical Outcomes in Patients With Atrial Fibrillation.
Yu HT; Yang PS; Jang E; Kim TH; Uhm JS; Kim JY; Pak HN; Lee MH; Lip GYH; Joung B
J Am Heart Assoc; 2020 Jun; 9(12):e014177. PubMed ID: 32495677
[TBL] [Abstract][Full Text] [Related]
4. Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation.
Chan YH; Chao TF; Chen SW; Lee HF; Yeh YH; Huang YC; Chang SH; Kuo CT; Lip GYH; Chen SA
Heart Rhythm; 2020 Dec; 17(12):2102-2110. PubMed ID: 32702416
[TBL] [Abstract][Full Text] [Related]
5. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry.
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli G; Reiffel J; Singer DE; Peterson ED; Piccini JP;
J Am Coll Cardiol; 2016 Dec; 68(24):2597-2604. PubMed ID: 27978942
[TBL] [Abstract][Full Text] [Related]
6. Modification of In-Hospital Recommendation and Prescription of Anticoagulants for Secondary Prevention of Stroke after Launch of Direct Oral Anticoagulants and Change of National Guidelines.
Gronemann C; Hause S; Assmann A; Neumann J; Schreiber S; Heinze HJ; Goertler M
Cerebrovasc Dis; 2020; 49(4):412-418. PubMed ID: 32756054
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes of Off-Label Dosing of Direct Oral Anticoagulant Therapy Among Japanese Patients With Atrial Fibrillation Identified From the SAKURA AF Registry.
Murata N; Okumura Y; Yokoyama K; Matsumoto N; Tachibana E; Kuronuma K; Oiwa K; Matsumoto M; Kojima T; Hanada S; Nomoto K; Arima K; Takahashi F; Kotani T; Ikeya Y; Fukushima S; Itoh S; Kondo K; Chiku M; Ohno Y; Onikura M; Hirayama A;
Circ J; 2019 Mar; 83(4):727-735. PubMed ID: 30726797
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program.
Chao TF; Hong KS; Lee BC; De Caterina R; Kirchhof P; Reimitz PE; Chen C; Unverdorben M; Wang CC
J Chin Med Assoc; 2021 May; 84(5):485-490. PubMed ID: 33742992
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation.
Bassand JP; Accetta G; Al Mahmeed W; Corbalan R; Eikelboom J; Fitzmaurice DA; Fox KAA; Gao H; Goldhaber SZ; Goto S; Haas S; Kayani G; Pieper K; Turpie AGG; van Eickels M; Verheugt FWA; Kakkar AK;
PLoS One; 2018; 13(1):e0191592. PubMed ID: 29370229
[TBL] [Abstract][Full Text] [Related]
10. Direct Anticoagulants Versus Vitamin K Antagonists in Patients Aged 80 Years or Older With Atrial Fibrillation in a "Real-world" Nationwide Registry: Insights From the FANTASIIA Study.
Ortiz MR; Muñiz J; Esteve-Pastor MA; Marín F; Roldán I; Cequier A; Martínez-Sellés M; Saldivar HG; Bertomeu V; Anguita M
J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):316-323. PubMed ID: 32228180
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and risk of inappropriate dosing of direct oral anticoagulants in two Swiss atrial fibrillation registries.
Montrasio G; Reiner MF; Wiencierz A; Aeschbacher S; Baumgartner C; Rodondi N; Kühne M; Moschovitis G; Preiss H; Coslovsky M; De Perna ML; Bonati LH; Conen D; Osswald S; Beer JH; Koepfli P;
Vascul Pharmacol; 2022 Dec; 147():107120. PubMed ID: 36182083
[TBL] [Abstract][Full Text] [Related]
12. Pattern and Impact of Off-label Underdosing of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Who are Indicated for Standard Dosing.
Cho MS; Yun JE; Park JJ; Kim YJ; Lee J; Kim H; Park DW; Nam GB
Am J Cardiol; 2020 May; 125(9):1332-1338. PubMed ID: 32098658
[TBL] [Abstract][Full Text] [Related]
13. Stroke prevention in patients from Latin American countries with non-valvular atrial fibrillation: Insights from the GARFIELD-AF registry.
Jerjes-Sanchez C; Corbalan R; Barretto ACP; Luciardi HL; Allu J; Illingworth L; Pieper KS; Kayani G;
Clin Cardiol; 2019 May; 42(5):553-560. PubMed ID: 30873623
[TBL] [Abstract][Full Text] [Related]
14. Stroke prevention, 1-year clinical outcomes and healthcare resource utilization in patients with atrial fibrillation in France: Data from the GARFIELD-AF registry.
Le Heuzey JY; Bassand JP; Berneau JB; Cozzolino P; D'Angiolella L; Doucet B; Mantovani LG; Martelet M; Mouallem J; Muller JJ; Pieper K;
Arch Cardiovasc Dis; 2018 Dec; 111(12):749-757. PubMed ID: 29861295
[TBL] [Abstract][Full Text] [Related]
15. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.
Fox KAA; Lucas JE; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Goldhaber SZ; Goto S; Haas S; Hacke W; Kayani G; Oto A; Mantovani LG; Misselwitz F; Piccini JP; Turpie AGG; Verheugt FWA; Kakkar AK;
BMJ Open; 2017 Dec; 7(12):e017157. PubMed ID: 29273652
[TBL] [Abstract][Full Text] [Related]
16. Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry.
Goto S; Angchaisuksiri P; Bassand JP; Camm AJ; Dominguez H; Illingworth L; Gibbs H; Goldhaber SZ; Goto S; Jing ZC; Haas S; Kayani G; Koretsune Y; Lim TW; Oh S; Sawhney JPS; Turpie AGG; van Eickels M; Verheugt FWA; Kakkar AK;
J Am Heart Assoc; 2019 Feb; 8(3):e010510. PubMed ID: 30717616
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Clinical Outcomes of Underdosed Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Atrial Flutter.
Ashraf H; Agasthi P; Shanbhag A; Mehta RA; Rattanawong P; Allam M; Pujari SH; Mookadam F; Freeman WK; Srivathsan K; Sorajja D; Shen WK; Noseworthy PA; Yang EH; Masry HZE; Yao X; Mulpuru SK; Beohar N; Holmes DR; Arsanjani R
Am J Med; 2021 Jun; 134(6):788-796. PubMed ID: 33444586
[TBL] [Abstract][Full Text] [Related]
18. Middle East Treatment Strategies and Clinical Outcomes in Patients with Atrial Fibrillation: One-Year Follow-up Data from Garfield-AF Study.
Sayin BY; Al Mahmeed W; Ragy HI; Elbahry A; Virdone S; Kakkar AK; Ersanlı M; Oto A
Adv Ther; 2021 May; 38(5):2391-2405. PubMed ID: 33772428
[TBL] [Abstract][Full Text] [Related]
19. Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II).
Steinberg BA; Shrader P; Pieper K; Thomas L; Allen LA; Ansell J; Chan PS; Ezekowitz MD; Fonarow GC; Freeman JV; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli GV; Reiffel JA; Singer DE; Peterson ED; Piccini JP;
J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29453305
[TBL] [Abstract][Full Text] [Related]
20. Why are outcomes different for registry patients enrolled prospectively and retrospectively? Insights from the global anticoagulant registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).
Fox KAA; Accetta G; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Kayani G; Kakkar AK;
Eur Heart J Qual Care Clin Outcomes; 2018 Jan; 4(1):27-35. PubMed ID: 28950344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
